Literature DB >> 17475834

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

Martin Duddy1, Masaaki Niino, Femina Adatia, Sherry Hebert, Mark Freedman, Harry Atkins, Ho Jin Kim, Amit Bar-Or.   

Abstract

Although recent animal studies have fuelled growing interest in Ab-independent functions of B cells, relatively little is known about how human B cells and their subsets may contribute to the regulation of immune responses in either health or disease. In this study, we first confirm that effector cytokine production by normal human B cells is context dependent and demonstrate that this involves the reciprocal regulation of proinflammatory and anti-inflammatory cytokines. We further report that this cytokine network is dysregulated in patients with the autoimmune disease multiple sclerosis, whose B cells exhibit a decreased average production of the down-regulatory cytokine IL-10. Treatment with the approved chemotherapeutic agent mitoxantrone reciprocally modulated B cell proinflammatory and anti-inflammatory cytokines, establishing that the B cell cytokine network can be targeted in vivo. Prospective studies of human B cells reconstituting following in vivo depletion suggested that different B cell subsets produced distinct effector cytokines. We confirmed in normal human B cell subsets that IL-10 is produced almost exclusively by naive B cells while the proinflammatory cytokines lymphotoxin and TNF-alpha are largely produced by memory B cells. These results point to an in vivo switch in the cytokine "program" of human B cells transitioning from the naive pool to the memory pool. We propose a model that ascribes distinct and proactive roles to memory and naive human B cell subsets in the regulation of memory immune responses and in autoimmunity. Our findings are of particular relevance at a time when B cell directed therapies are being applied to clinical trials of several autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475834     DOI: 10.4049/jimmunol.178.10.6092

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  242 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

Review 2.  Development of anti-CD20 therapy for multiple sclerosis.

Authors:  Beatrix Bartok; Gregg J Silverman
Journal:  Exp Cell Res       Date:  2011-04-12       Impact factor: 3.905

Review 3.  Regulatory B cells in autoimmunity: developments and controversies.

Authors:  Claudia Mauri; Paul A Blair
Journal:  Nat Rev Rheumatol       Date:  2010-09-21       Impact factor: 20.543

Review 4.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

5.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

6.  [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].

Authors:  C Meyer; N Ansorge; I Siglienti; S Salmen; A Stroet; H Nückel; U Dührsen; P R Ritter; W E Schmidt; R Gold; A Chan
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214

Review 7.  Neuroinflammation: Ways in Which the Immune System Affects the Brain.

Authors:  Richard M Ransohoff; Dorothy Schafer; Angela Vincent; Nathalie E Blachère; Amit Bar-Or
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 8.  The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Authors:  Stephen L Hauser
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

Review 9.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

Review 10.  Re-thinking the functions of IgA(+) plasma cells.

Authors:  Jennifer L Gommerman; Olga L Rojas; Jörg H Fritz
Journal:  Gut Microbes       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.